Mersana Therapeutics Shareholder Alert: Kaplan Fox Launches Investigation into Mersana Therapeutics, Inc. for Potential Securities Violations
23 juin 2023 16h30 HE
|
Kaplan Fox & Kilsheimer LLP
NEW YORK, June 23, 2023 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating potential claims on behalf of investors who purchased Mersana Therapeutics, Inc....
INVESTOR ALERT: Kaplan Fox Investigates Mersana Therapeutics, Inc. (Nasdaq: MRSN)
19 juin 2023 18h54 HE
|
Kaplan Fox & Kilsheimer LLP
NEW YORK, June 19, 2023 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating potential claims on behalf of investors who purchased Mersana Therapeutics, Inc....
Mersana Therapeutics to Present at the Credit Suisse 27th Annual Healthcare Conference
08 nov. 2018 17h00 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
Mersana Therapeutics to Host Conference Call Announcing Third Quarter 2018 Financial Results and Business Updates
06 nov. 2018 17h00 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
Mersana Therapeutics to Present at Upcoming Investor Conferences
26 sept. 2018 16h03 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 26, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
Mersana Therapeutics Presents New Preclinical Data on XMT-1536 at the International Association for the Study of Lung Cancer (IASLC) 19th World Conference on Lung Cancer
25 sept. 2018 08h00 HE
|
Mersana Therapeutics, Inc.
Novel Immunohistochemistry Assay Distinguishes Non-Small Cell Lung Cancer (NSCLC) Subtypes XMT-1536 Phase 1 Dose Escalation Ongoing With Data Reporting in the First Half of 2019 CAMBRIDGE, Mass.,...
Mersana Therapeutics Announces Second Quarter 2018 Financial Results and Provides Business Updates
14 août 2018 16h20 HE
|
Mersana Therapeutics, Inc.
Response to the FDA Partial Clinical Hold Submitted This Week Strong Balance Sheet with a cash position of $97M to close Q2 CAMBRIDGE, Mass., Aug. 14, 2018 (GLOBE NEWSWIRE) -- Mersana...
Mersana Therapeutics to Present at the Wedbush PacGrow Healthcare Conference
08 août 2018 16h03 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 08, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
Mersana Therapeutics to Host Conference Call Announcing Second Quarter 2018 Financial Results and Business Updates
08 août 2018 16h01 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 08, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
Mersana Therapeutics Announces Partial Clinical Hold for XMT-1522 Clinical Trial
19 juil. 2018 08h00 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., July 19, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc.(NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...